Joseph Ziegler - 17 Aug 2023 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Reporting relationship: Principal Financial Officer
Issuer ticker: TXMD
Reported as of: 17 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Aug 2023, 16:22:58 UTC
Prior SEC filing: 15 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Joseph Ziegler

Key filing fact

Joseph Ziegler filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 21 Aug 2023.

Key facts

This page summarizes Joseph Ziegler's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Aug 2023, 16:22.

Change

Previous filing in this sequence was filed on 15 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TXMD transaction

Common Stock

Award

Transaction value: $0
Shares: +7,500
Change %
Price: $0.000000
Shares after: 7,500
Date: 17 Aug 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares of common stock of the Issuer are to be acquired upon the vesting of restricted stock units ("RSUs") granted to the Reporting Person. The RSUs shall fully vest on the earlier of August 17, 2024 or a Change in Control of the Issuer (as defined in the Issuer's 2019 Stock Incentive Plan).